Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 plus azacitidine versus placebo plus azacitidine in previously untreated IDH1-mutant AML
NL-OMON53147Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Ivosidenib + azacitidine with Placebo + azacitidine (2 arms). Primary endpoint: Event-free survival. Started Feb 2018; status: active, not recruiting.
02
Drugs
ivosidenibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON53147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53147.